GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome.
冠状病毒木瓜蛋白酶样蛋白酶(Plpro)抑制剂(SARS-COV和SARS-CoV-2 PLpro的IC50值分别为0.6和0.8μM)。抑制SARS-CoV PLpro的去泛素活性。对人类去泛素化酶没有抑制作用。改善SARS-CoV感染后的细胞活力。在SACos-CoV-2感染CaCo-2细胞后,抑制SARS-CoV-2病毒复制并诱导抗病毒免疫信号通路。
GRL-0617 is a cell penetrant non-cytotoxic and potent inhibitor of the SARS-CoV -2 papain-like protease (SCoV2-PLpro) and SCoV-PLpro. GRL-0617 reversibly binds to SCoV2-PLpro and disrupts its interaction with Interferon-stimulated gene 15 (ISG15). GRL-0617 poorly affects (> 100 μM) the activities of MERS PLpro, a series of cysteine proteases, including the human deubiquitinating enzymes HAUSP, USP18, UCH-L1, UCH-L3, and a papain-like protease (PLP2) from the human coronavirus NL63. GRL-0617 suppress SARS-CoV-2 infection and promote anti-viral immunity.